It is postulated that low production of IL-2 can suppress the antitumor response via the antibody-dependent cellular cytotoxicity (ADCC) seen in NHL patients, thus increasing the susceptibility to develop NHL [4]. This evidence concerns the gene IL2 and non-Hodgkin lymphoma.